CClinicalTrials.gg
Not yet recruitingNCT07809191Updated Sep 9, 2026

Hair Regrowth Following Partial Thickness Removal of SSCIS

An interventional study of Partial Thickness Excision in Squamous Cell Carcinoma (Skin), Squamous Cell Carcinoma in Situ and Alopecia, sponsored by The Cooper Health System. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by The Cooper Health System · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Participants are being approached to participate in this study because they are undergoing surgery for a skin cancer known as squamous cell carcinoma in situ (SCCIS) on the scalp. Standard surgical techniques may remove deeper structures that contain hair follicles, which can result in permanent hair loss. This study evaluates whether a modified surgical technique, known as partial thickness excision, can preserve hair growth and improve cosmetic outcomes. Participation involves minimal risk beyond the standard risks of Mohs surgery. If patients choose to participate, their surgery will be performed using this technique, and photographs will be taken over time to evaluate hair regrowth and healing.

02

Conditions studied

  • Squamous Cell Carcinoma (Skin)
  • Squamous Cell Carcinoma in Situ
  • Alopecia

Keywords

  • mohs micrographic surgery
  • partial thickness excision
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Adults ≥ 18 years old
  • Histologically confirmed SCCIS
  • Lesions located in the hair-bearing scalp
  • Ability to provide informed consent

Exclusion criteria

Exclusion Criteria:

  • Invasive, poorly differentiated, or high-risk SCC features (e.g., perineural invasion)
  • Recurrent SCC at the same site
  • Prior radiation therapy to the scalp
  • Scarring alopecia or active inflammatory scalp disease at the treatment site
  • Immunosuppression that, in the investigator's judgement, increases oncologic risk
  • Use of topical minoxidil, oral minoxidil, finasteride, spironolactone, or other hair-growth promoting agents
04

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Partial Thickness Excision

    Participants will receive excision of their squamous cell carcinoma in situ of the scalp via partial thickness excision (removal of epidermal and superficial dermal tissue) in an effort to preserve hair follicles and hair growth potential.

    Procedure: Partial Thickness Excision

Interventions

  • ProcedurePartial Thickness Excision

    Participants will receive excision of their squamous cell carcinoma in situ of the scalp via partial thickness excision (removal of epidermal and superficial dermal tissue) in an effort to preserve hair follicles and hair growth potential.

05

What researchers measure

Primary outcomes

  1. Hair Growth measured clinically by hair density percentage compared to baseline photo

    To evaluate hair growth following partial thickness excision of SCCIS at 3 and 6 months post-procedure.

    Time frame: 3 and 6 months post-procedure.

Secondary outcomes

  1. Clearance of SCCIS measured by Mohs surgeons' interpretation of margins on surgical slides.

    To assess clinical and histologic clearance of SCCIS treated with partial-thickness excision.

    Time frame: Immediately following the final Mohs stage during the index procedure

  2. Patient Satisfaction measured via patient satisfaction questionnaire

    To evaluate patient-reported satisfaction with hair density and cosmetic outcome. "Are you satisfied with amount of hair//appearance of skin/result of treatment?" etc. on scale of 1-10. 1 being not satisfied and 10 being very satisfied/.

    Time frame: 3 and 6 months post-procedure

  3. Complications

    To document wound-healing, complications, and the need for additional treatment.

    Time frame: 2 weeks post-procedure, 3 months post-procedure, and 6 months post-procedure

06

Study locations

No study locations are listed for this record.

07

Registry details

Key details

Study ID
NCT07809191
Lead sponsor
The Cooper Health System
Responsible party
Naomi Lawrence (Principle Investigator, The Cooper Health System) — Principal investigator
First posted
Sep 9, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Jul 17, 2027 (estimated)
Completion
Jul 17, 2028 (estimated)
Last update
Sep 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion